Literature DB >> 18713828

Possible relationship between the risk of Japanese bladder cancer cases and the CYP4B1 genotype.

Takamitsu Sasaki1, Miho Horikawa, Kazuhiko Orikasa, Makoto Sato, Yoichi Arai, Yoshitaka Mitachi, Michinao Mizugaki, Masaaki Ishikawa, Masahiro Hiratsuka.   

Abstract

Cytochrome P450 4B1 (CYP4B1) is involved in the metabolism of several xenobiotics, such as 2-aminofluorene, 2-naphthylamine and benzidine. CYP4B1 allelic variants CYP4B1*1-*7 were recently identified. We thus hypothesized that CYP4B1 genotypes may modify bladder cancer risk. We examined the CYP4B1 genotypes in 169 bladder cancer cases and 190 hospital controls using a hybridization probe assay. Among the CYP4B1 genotypes observed, the most frequent genotypes in both the groups were CYP4B1*1/*1, *1/*2, *1/*3 and *2/*2. Logistic regression analysis revealed that the subjects carrying the CYP4B1*1/*2 or *2/*2 genotypes had a 1.75-fold increased risk of bladder cancer (95% CI=1.03-2.95, P = 0.038) compared with the subjects carrying the CYP4B1*1/*1 genotype. We demonstrated the first genetic study regarding the association of CYP4B1 with bladder cancer. Our results suggest that CYP4B1 genotypes might have an effect on the risk of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713828     DOI: 10.1093/jjco/hyn081

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Specific survivin dual fluorescence resonance energy transfer molecular beacons for detection of human bladder cancer cells.

Authors:  Zhi-qiang Wang; Jun Zhao; Jin Zeng; Kai-jie Wu; Yu-le Chen; Xin-yang Wang; Luke S Chang; Da-lin He
Journal:  Acta Pharmacol Sin       Date:  2011-10-24       Impact factor: 6.150

2.  Suppression of cytochrome P450 4B1: An early event in adrenocortical tumorigenesis.

Authors:  Timothy D Murtha; Reju Korah; Tobias Carling
Journal:  Surgery       Date:  2016-11-16       Impact factor: 3.982

3.  Multiple criteria optimization joint analyses of microarray experiments in lung cancer: from existing microarray data to new knowledge.

Authors:  Katia I Camacho-Cáceres; Juan C Acevedo-Díaz; Lynn M Pérez-Marty; Michael Ortiz; Juan Irizarry; Mauricio Cabrera-Ríos; Clara E Isaza
Journal:  Cancer Med       Date:  2015-10-16       Impact factor: 4.452

Review 4.  Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications.

Authors:  Yazun Bashir Jarrar; Su-Jun Lee
Journal:  Int J Mol Sci       Date:  2019-08-31       Impact factor: 5.923

5.  CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma.

Authors:  Xiaoling Liu; Yichen Jia; Changyuan Shi; Dechen Kong; Yuanming Wu; Tiantian Zhang; Anjie Wei; Dan Wang
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

6.  Identifying a hypoxia related score to predict the prognosis of bladder cancer: a study with The Cancer Genome Atlas (TCGA) database.

Authors:  Zhenan Zhang; Qinhan Li; Aolin Li; Feng Wang; Zhicun Li; Yisen Meng; Qian Zhang
Journal:  Transl Androl Urol       Date:  2021-12

7.  Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population.

Authors:  Natnicha Wankaew; Pajaree Chariyavilaskul; Monpat Chamnanphon; Adjima Assawapitaksakul; Wanna Chetruengchai; Monnat Pongpanich; Vorasuk Shotelersuk
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

8.  Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder.

Authors:  Maria V Luna-Velez; Jelmer J Dijkstra; Marina A Heuschkel; Frank P Smit; Guillaume van de Zande; Dominique Smeets; J P Michiel Sedelaar; Michiel Vermeulen; Gerald W Verhaegh; Jack A Schalken
Journal:  Mol Oncol       Date:  2021-05-22       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.